Premium
The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus
Author(s) -
Mathur G.,
Noronha B.,
Rodrigues E.,
Davis G.
Publication year - 2007
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2006.00644.x
Subject(s) - medicine , diabetes mellitus , angiotensin receptor blockers , type 2 diabetes mellitus , disease , intensive care medicine , coronary heart disease , angiotensin ii , endocrinology , renin–angiotensin system , receptor , blood pressure
Angiotensin II Receptor blockers (ARBs) are an important addition to the current range of medications available for treating a wide spectrum of diseases including cardiovascular diseases. Coronary heart disease (CHD) is the most common cause of death in the United Kingdom and worldwide. More importantly, the presence of the metabolic syndrome and the likelihood of diabetes mellitus taking on epidemic proportions in the years to come all threaten to maintain the mortality rate due to CHD. This review article focuses on the clinical studies that have helped define the trends in the usage of these agents in the prevention and treatment of diabetes mellitus and its complications and also explores possible mechanisms of action and future developments.